Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome
Erik S G Stroes,Veronica J Alexander,Ewa Karwatowska-Prokopczuk,Robert A Hegele,Marcello Arca,Christie M Ballantyne,Handrean Soran,Thomas A Prohaska,Shuting Xia,Henry N Ginsberg,Joseph L Witztum,Sotirios Tsimikas,Balance Investigators,Jean Bergeron,Sophie Bernard,Daniel Gaudet,Philippe Moulin,Rene Valero,Bruno Verges,Istvan Reiber,Osamah Hussein,Antonia Alberti,Maurizio Averna,Gabriella Iannuzzo,Erik Sjoerd,Gerard Stroes,Kjetil Retterstol,Tiago Curdia Goncalves,Joao Sequeira Duarte,Katarina Raslova,Agustin Blanco,Jose Luis Diaz Diaz,Ovidio Muniz,Daniel Zambon,Mats Eriksson,Stefano Romeo,Devaki Nair,Anthony Wierzbicki,Zahid Ahmad,Archna Bajaj,Christie Ballantyne,Alan Brown,Seth Baum,Henry Ginsberg,Ira Goldberg,Kenneth Hilty,MacRae Linton,Patrick Moriarty,Anthony Morise,Elif Oral,Paul Rosenblit,Eveline Stock,James Trippi,Richard C Becker,P Barton Duell,Jamie P Dwyer,Willis C Maddrey,Lee-Jen Wei,Marco Bruno,Philippe Ruszniewski,George Webster
DOI: https://doi.org/10.1056/NEJMoa2400201
2024-05-16
Abstract:Background: Familial chylomicronemia syndrome is a genetic disorder associated with severe hypertriglyceridemia and severe acute pancreatitis. Olezarsen reduces the plasma triglyceride level by reducing hepatic synthesis of apolipoprotein C-III. Methods: In a phase 3, double-blind, placebo-controlled trial, we randomly assigned patients with genetically identified familial chylomicronemia syndrome to receive olezarsen at a dose of 80 mg or 50 mg or placebo subcutaneously every 4 weeks for 49 weeks. There were two primary end points: the difference between the 80-mg olezarsen group and the placebo group in the percent change in the fasting triglyceride level from baseline to 6 months, and (to be assessed if the first was significant) the difference between the 50-mg olezarsen group and the placebo group. Secondary end points included the mean percent change from baseline in the apolipoprotein C-III level and an independently adjudicated episode of acute pancreatitis. Results: A total of 66 patients underwent randomization; 22 were assigned to the 80-mg olezarsen group, 21 to the 50-mg olezarsen group, and 23 to the placebo group. At baseline, the mean (±SD) triglyceride level among the patients was 2630±1315 mg per deciliter, and 71% had a history of acute pancreatitis within the previous 10 years. Triglyceride levels at 6 months were significantly reduced with the 80-mg dose of olezarsen as compared with placebo (-43.5 percentage points; 95% confidence interval [CI], -69.1 to -17.9; P<0.001) but not with the 50-mg dose (-22.4 percentage points; 95% CI, -47.2 to 2.5; P = 0.08). The difference in the mean percent change in the apolipoprotein C-III level from baseline to 6 months in the 80-mg group as compared with the placebo group was -73.7 percentage points (95% CI, -94.6 to -52.8) and between the 50-mg group as compared with the placebo group was -65.5 percentage points (95% CI, -82.6 to -48.3). By 53 weeks, 11 episodes of acute pancreatitis had occurred in the placebo group, and 1 episode had occurred in each olezarsen group (rate ratio [pooled olezarsen groups vs. placebo], 0.12; 95% CI, 0.02 to 0.66). Adverse events of moderate severity that were considered by a trial investigator at the site to be related to the trial drug or placebo occurred in 4 patients in the 80-mg olezarsen group. Conclusions: In patients with familial chylomicronemia syndrome, olezarsen may represent a new therapy to reduce plasma triglyceride levels. (Funded by Ionis Pharmaceuticals; Balance ClinicalTrials.gov number, NCT04568434.).